Bryan Johnson Longevity: What He Has Said About Medication and His Blueprint Protocol

Who Is Bryan Johnson and What Is Blueprint?

Bryan Johnson is a technology entrepreneur who sold his company Braintree to PayPal for $800 million in 2013. He has since directed significant personal resources toward a self-experiment he calls Blueprint, a fully documented, physician-supervised protocol designed to slow or reverse biological aging. Blueprint is not a product he sells in the traditional sense. He publishes the protocol openly at blueprint.bryanjohnson.co and across social media.

The protocol is structured around three pillars: precise nutrition (a vegan-heavy, calorie-controlled diet), aggressive sleep optimization, and a large stack of pharmaceutical and nutraceutical compounds. Johnson has said publicly, in interviews including a 2023 appearance on the Lex Fridman Podcast, that every decision in the protocol is made by his medical team based on measurement, not intuition.

The Role of Medical Supervision

Johnson's physician team is led by Dr. Oliver Zolman, who describes his specialty as longevity medicine. The team includes cardiologists, urologists, dermatologists, and ophthalmologists who track roughly 70 biomarkers at regular intervals. Johnson has stated that no drug or supplement is added to his stack without review of peer-reviewed evidence and without monitoring for adverse effects.

This level of oversight is clinically meaningful. Off-label drugs like rapamycin carry real risks, including immunosuppression at transplant doses, and their use in healthy adults for longevity is not supported by current FDA-approved labeling. The ITP (Interventions Testing Program), funded by the National Institute on Aging, has generated the most rigorous animal data on these compounds, but translation to humans remains an open research question. [1]

Why His Protocol Gets Clinical Attention

Johnson is not the only person experimenting with longevity drugs, but he is the most publicly documented. His willingness to share full labs, MRI data, continuous glucose monitor traces, and stool microbiome results has made Blueprint a reference point in longevity medicine circles. The data are self-reported and not peer-reviewed as a cohort study, which limits their scientific weight. Still, clinicians and researchers reference them because the documentation is unusually granular.

What Bryan Johnson Has Said About Specific Medications

Johnson's public statements about individual drugs are scattered across podcast interviews, his Substack, his YouTube channel, and posts on X. The following sections compile and contextualize what he has said about the most clinically significant compounds in his stack.

Rapamycin

Rapamycin (sirolimus) is an mTOR inhibitor approved by the FDA for organ transplant rejection prevention at daily doses of 2-6 mg. Johnson has stated he takes rapamycin at approximately 13 mg once weekly, a dosing schedule based on ITP mouse data and on research from Dr. Matt Kaeberlein's Dog Aging Project. [2]

Johnson said in a 2023 YouTube video: "Rapamycin is the most well-studied longevity compound in animals. It extends lifespan in every organism it has been tested in, including mice at middle age." That claim is broadly accurate for the ITP data. In the ITP's 2009 landmark study published in Nature (Harrison et al., N=1,901 mice across three sites), late-life rapamycin feeding increased median lifespan by 9% in males and 14% in females. [3]

The human evidence is far thinner. No randomized controlled trial has shown lifespan extension in healthy humans on rapamycin. A 2014 study in Science Translational Medicine (Mannick et al.) showed that weekly low-dose rapamycin (0.5 mg daily or 5 mg weekly) improved influenza vaccine response in older adults, suggesting some immune rejuvenation effect. [4] Johnson has cited this trial to justify weekly rather than daily dosing.

Risks include mouth sores, elevated lipids, impaired wound healing, and potential immunosuppression at higher doses. Johnson says he monitors white blood cell count, triglycerides, and fasting glucose quarterly to screen for these effects.

Metformin

Metformin is a biguanide approved for type 2 diabetes. Johnson has acknowledged taking metformin at 1,500-1,700 mg per day and has referenced the TAME trial (Targeting Aging with Metformin), a NIH-funded randomized controlled trial enrolling approximately 3,000 adults aged 65-79 to assess whether metformin delays age-related disease. [5]

He has also acknowledged the controversy around metformin and exercise. A 2019 randomized trial in Aging Cell (Walton et al., N=53) found that metformin blunted the increase in mitochondrial respiration and muscle mass normally produced by aerobic exercise training. [6] Johnson has said in podcast interviews that he accepts this trade-off given what he views as metformin's broader systemic benefits, though he noted the uncertainty on his Substack in early 2024.

Acarbose

Acarbose is an alpha-glucosidase inhibitor approved for type 2 diabetes that slows intestinal carbohydrate absorption. In ITP studies, acarbose extended median lifespan by 22% in male mice, one of the largest effects seen in that program. [1] Johnson has cited this figure directly and takes acarbose at approximately 200 mg with meals.

His stated rationale is postprandial glucose blunting. Continuous glucose monitor data he has shared publicly show near-flat glucose responses to meals. Acarbose's main adverse effects are gastrointestinal: flatulence, diarrhea, and abdominal discomfort, which Johnson has mentioned tolerating at lower doses initially.

Testosterone and Finasteride

Johnson has been open about taking testosterone at physiologic replacement levels following testing that showed his endogenous testosterone in the low-normal range for his age group. Finasteride at 1 mg per day is included to manage dihydrotestosterone conversion and limit hair loss, a common co-prescription in TRT protocols.

He has not framed testosterone as a longevity drug per se, but has described it as part of optimizing hormonal physiology to support muscle maintenance and recovery. The American College of Endocrinology notes that testosterone therapy is indicated for symptomatic hypogonadism confirmed by two low morning total testosterone measurements. [7]

Telmisartan

Telmisartan is an angiotensin receptor blocker (ARB) primarily prescribed for hypertension. Johnson has reported taking it at 40 mg per day. His stated rationale is dual: blood pressure control and PPAR-gamma agonist activity, which some researchers believe may have metabolic benefits. A 2011 meta-analysis in the Journal of the American Medical Association (ONTARGET/TRANSCEND data, N=25,620) showed telmisartan reduced cardiovascular events versus placebo in high-risk patients without established hypertension. [8] Johnson does not have hypertension by conventional criteria, making this an off-label use based on risk-reduction modeling.

The Supplement Stack: Key Compounds

Beyond prescription drugs, Johnson's stack includes a large number of supplements. The most clinically discussed include NMN, lithium orotate, vitamin D3, omega-3 fatty acids, lycopene, and lutein.

NMN (Nicotinamide Mononucleotide)

Johnson takes NMN at approximately 2 g per day to support NAD+ biosynthesis. He has cited preclinical data showing NAD+ decline with age and animal studies demonstrating reversal of some age-related physiological markers with NMN supplementation. A 2021 randomized controlled trial in npj Aging and Mechanisms of Disease (Yoshino et al., N=25 postmenopausal women with prediabetes) showed NMN 250 mg per day improved skeletal muscle insulin sensitivity, though this was a small, specific population. [9] The dose Johnson takes exceeds that trial's dose by eightfold. Human evidence for NMN at 2 g per day remains limited.

Low-Dose Lithium Orotate

Johnson has stated he takes lithium orotate at approximately 1 mg per day, citing observational data linking higher environmental lithium levels in drinking water to lower rates of suicide and neurodegenerative disease. A 2017 systematic review in the British Journal of Psychiatry (Fajutrao et al. / Vita et al. Data) and separate epidemiological studies have explored this association. [10] This is a very low dose compared with lithium carbonate used in bipolar disorder (which reaches serum levels of 0.6-1.2 mEq/L). The longevity signal is hypothesis-generating, not confirmatory.

Vitamin D3, K2, and Omega-3s

These are among the better-supported supplements in his stack. A 2019 Cochrane review found that vitamin D supplementation reduced all-cause mortality in older adults (RR 0.96, 95% CI 0.93-0.99). [11] Johnson targets 25-hydroxyvitamin D serum levels of 60-80 ng/mL, above the standard sufficient threshold of 30 ng/mL but within ranges some longevity clinicians use. Omega-3 supplementation at 3.3 g EPA+DHA per day is supported by REDUCE-IT (N=8,179), which showed icosapentaenoic acid (EPA) at 4 g per day reduced major adverse cardiovascular events by 25% in high-triglyceride patients on statins. [12]

What the Blueprint Data Actually Show

Johnson publishes biological age estimates from multiple testing platforms, including methylation clocks (Horvath clock, DunedinPACE), organ-specific aging scores from MRI, and performance benchmarks. He has reported that his epigenetic age, as measured by GrimAge and DunedinPACE algorithms, is lower than his chronological age of 47 by several years on some tests.

Interpreting these numbers requires caution. Methylation clocks were trained primarily to predict time-to-death or disease onset in population cohorts; their accuracy as real-time feedback tools for individual protocol optimization is unvalidated. A 2022 review in Nature Aging noted that current epigenetic clocks have substantial within-person variability and may not accurately reflect the underlying biology of aging in people making aggressive lifestyle and pharmaceutical interventions. [13]

Johnson himself has acknowledged this limitation publicly. In a 2024 Substack post, he wrote that he views his biomarker data as directional signals rather than definitive proof of biological rejuvenation. That framing is clinically appropriate.

What Clinicians Should Know When Patients Ask About Blueprint

Patients presenting to longevity or primary care clinicians asking about Blueprint-style protocols are increasingly common. The following clinical considerations apply.

Which Drugs Have Meaningful Human Evidence

Metformin has the strongest human safety record of any drug in the stack, with decades of use in type 2 diabetes and a strong observational signal for reduced all-cause mortality in diabetic cohorts. The TAME trial, expected to report results around 2026-2027, will provide the first prospective human longevity data. Telmisartan and testosterone (in hypogonadal men) have established clinical profiles. Rapamycin's weekly low-dose regimen in healthy adults has the thinnest prospective human evidence and carries real immunosuppression risk at higher doses.

Baseline Labs Before Considering Any Off-Label Use

Any clinician considering off-label rapamycin, metformin, or acarbose for a non-diabetic, non-transplant patient should obtain: fasting metabolic panel, CBC with differential, HbA1c, fasting insulin, lipid panel, testosterone (total and free, morning), and eGFR. Metformin is contraindicated at eGFR <30 mL/min/1.73m2. Rapamycin requires monitoring of lipids, blood counts, and wound healing history.

The Exercise-Metformin Interaction

The Walton et al. Finding that metformin may blunt exercise adaptations is a real clinical consideration for patients who exercise regularly. Clinicians should discuss this trade-off. Some protocols use metformin only on non-exercise days, though this approach lacks RCT support.

Johnson's Own Caveats and Public Statements

Johnson has been consistent about labeling Blueprint as a personal experiment, not a recommendation for the general public. On multiple podcast appearances, he has said that his protocol is designed for his specific physiology, monitored continuously by specialists, and should not be self-administered based on internet research alone.

In a 2023 interview with TIME magazine, he stated: "I'm not telling anyone to do what I do. I'm sharing the data so that others, including researchers, can use it." That framing aligns with how clinical researchers treat n=1 case reports: informative as hypothesis-generators, not as practice guidelines.

The American Academy of Anti-Aging Medicine and the National Institute on Aging have both emphasized that no pharmacological intervention has been proven to extend human lifespan in a controlled trial as of 2025. [14] The TAME trial, the ITP's ongoing mouse studies, and emerging data from the Dog Aging Project represent the field's best current evidence-generation efforts.

Cost, Access, and the Privilege Problem

Johnson's protocol costs an estimated $2 million per year at its peak, a figure he has discussed publicly and is working to reduce through what he calls protocol optimization. A version of Blueprint supplements is commercially available at significantly lower cost, but the prescription drug components require physician oversight and are not covered by insurance for off-label longevity indications.

This creates an access gap that is worth naming directly. The interventions with the strongest evidence (diet quality, resistance exercise, sleep duration of 7-9 hours, blood pressure control, omega-3 supplementation) are available at low or no cost. The more speculative interventions (weekly rapamycin, high-dose NMN) require both financial resources and a clinician willing to prescribe off-label based on limited evidence.

A 2023 analysis in JAMA Internal Medicine noted that socioeconomic status remains one of the strongest predictors of longevity in the United States, with a 10-14 year life expectancy gap between the highest and lowest income quartiles. [15] No pharmaceutical protocol closes that gap without addressing its upstream determinants.